We founded InvestAcure because Alzheimer’s must be cured!

Our vision is to see a world where drug companies are owned by millions of spare change investors committed to curing Alzheimer's.

We believe that by bringing together a vast community of cure motivated spare change investors, brilliant scientists and well-managed companies, we can ensure that cutting edge scientific discoveries are turned into a lifesaving cure for Alzheimer's!

Our Team

Max TokarskyCEO

Social entrepreneur who built RAJE, a large educational non-profit and had the idea for InvestAcure when his daughter was battling cancer.

Ken Abramowitz Chief Investment Officer

NGN Capital, Co-founder & Managing General Partner, voted top pharmaceutical analyst by Institutional Investor Magazine, Wall Street Analyst Hall of Fame, MBA, Harvard Business School.

Chanan Kaufman EVP of Development,
InvestAcure Foundation

Experienced nonprofit & social impact executive, Founder of Nextdor, a social impact startup accelerator & Bizrael, a leading nonprofit connecting US & Israeli pharmaceutical & tech startups.

Lawrence Pine COO

COO Worked with Max as the COO of RAJE and joined him in co-founding the new company. MBA & IT background.

Grace Mutavu Executive Assistant

5 years communications & development, Communication Officer @ Smith & Lewis Global, BA Political Science & Government Smith College.

George Perry, PH.D Scientific Advisor

Editor-in-Chief of Journal of Alzheimer's, Dean UT-San Antonio, one of the top most-cited scientists in Neuroscience.

Pierre Tariot, MD Scientific Advisor

Director of the Banner Alzheimer’s Institute. Over 350 scientific papers, including several leading to FDA approval of treatments for Alzheimer's.

Hugo Geerts, PH.D Scientific Advisor

CSO of In Silico Biosciences, headed Johnson & Johnson Alzheimer’s research and developed one of only 5 approved Alzheimer’s drugs.

Adeboye Adejare, PH.D Scientific Advisor

NIH and Alzheimer’s Association national panels. Over 50 publications, 5 patents, and more than 100 presentations at conferences.

J. Thomas Vaughan, Ph.D Scientific Advisor

Columbia University – Director of MR Research – 45 patents – pioneer in development of MRI technology for diagnosis of Alzheimer’s.

Lon Schneider, Ph.D Scientific Advisor

Director of USC State of California Alzheimer’s Disease Center and the National Institute on Aging Alzheimer’s Disease Research Center. Editor-in-chief of Alzheimer’s & Dementia: Translational Research and Clinical Interventions.

Douglas J MacNeil, Ph.D Scientific Advisor

A leading expert in early-stage drug discovery directed Exploratory & Translational Sciences at Merck, scientific board of Alzheimer's Drug Discovery Foundation, 144 research publications.

Julie Fleming, Purple Sherpa CEO & Founder Advisor

Julie is a former patent litigator with a science background, and founder of a law-firm business consultancy. Julie’s father is a retired lawyer with Alzheimer’s and vascular dementia.

Beau Mann, Sober Grid CEO & Founder Advisor

Beau is an avid entrepreneur – starting and advising several digital companies. Member of the Forbes Technology Council and has been featured in the NY Times, Inc. Magazine, Entrepreneur Magazine, just to name a few.

Alex Geis Lead Tech Advisor

Founded 21Productions, licensed software to leading universities, CTO at TruOptik

Heidi V. Picket Advisor

Assistant Dean of MIT Sloan Master of Finance Program - a recognized expert on corporate development, business strategy, and global operations, served as Senior Managing Director at State Street Global Markets, President of the Verrill Foundation.